Siemens Healthineers and Mayo Clinic collaborate to improve care for neurodegenerative disease, cancer

Mayo Clinic pilot study demonstrates safety, feasibility of delivering chemotherapy at home

Findings from a pilot study conducted by Mayo Clinic researchers suggest that chemotherapy can be safely delivered in patients’ homes.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Mayo Clinic researchers use milk-derived nanoparticles to target aggressive bile duct cancer

Mayo Clinic researchers have developed a promising way to deliver treatment directly to cholangiocarcinoma tumors, a rare and aggressive bile duct cancer with limited treatment options, using milk-derived nanoparticles that act like guided delivery vehicles. The study points to a potential targeted genetic therapy designed to attack cancer cells while sparing healthy tissue.

March 20, 2026

Vol.52 No.11

Drugs & Targets

START, Trialing collaborate to expand access to oncology clinical trials across Europe

The START Center for Cancer Research, a community-based network of clinical trial sites specializing in early-phase oncology trials, announced a strategic partnership with Trialing, a platform dedicated to connecting physicians and patients to clinical trials, helping physicians rapidly identify, evaluate, and refer patients to appropriate studies.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment, according to a Mayo Clinic-led study.

February 27, 2026

Vol.52 No.08

Drugs & Targets

PharmaMar, Globant collaborate to accelerate oncology research with AI

Globant, a company focused on AI, and PharmaMar, developer of marine-derived anti-cancer drugs, announced a new collaboration designed to speed up cancer drug discovery through artificial intelligence.

February 20, 2026

Vol.52 No.07

Drugs & Targets

Labcorp and Roche collaborate to expand access to advanced precision testing

Labcorp announced its first U.S. commercial laboratory with an agreement to implement Roche’s cobas Mass Spec solution. This collaboration introduces fully automated mass spectrometry into routine clinical practice—accelerating turnaround times, improving accuracy, and expanding access to advanced diagnostics for patients and providers nationwide.

January 30, 2026

Vol.52 No.04

Siemens Healthineers and Mayo Clinic collaborate to improve care for neurodegenerative disease, cancer

YOU MAY BE INTERESTED IN

Mayo Clinic pilot study demonstrates safety, feasibility of delivering chemotherapy at home

Mayo Clinic researchers use milk-derived nanoparticles to target aggressive bile duct cancer

START, Trialing collaborate to expand access to oncology clinical trials across Europe

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

PharmaMar, Globant collaborate to accelerate oncology research with AI

Labcorp and Roche collaborate to expand access to advanced precision testing

Renew today!

Subscriber content

Never miss an issue!

Login